ImpaQ Ecosystem•Clarivate, Scopus & CORE Data
Clarivate WoS 2024 / 2025 Data
IMPAQ
WoS SCIE Q2Scopus Q2SCImago #3,649Review JournalHybrid

Expert Review of Clinical Immunology

Acronym:erm
•
Abbreviation (ISO):Expert Rev. Clin. Immunol
•
Identifier (ISSN):1744-666X(Print)/1744-8409(Online)
•
Publisher:Taylor and Francis Ltd.
Clarivate IF (2026)
4↑ +0.3
Journal Impact Factor
IF Trend↓
WoS Quartile
Q2
WoS SCIEJCR Quartile
Clarivate WoS JCR
WoS Categories↓
JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Expert Review of Clinical Immunology

WoS Q2
24573.4420183.9120193.7920204.4720215.1220224.420233.920243.7202542026
Annual Impact Factor Metric
Current (2026):4
Scopus SJR & RankScopus Q2
1.198
#3,649

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025
H-Index (2025)
85

85 papers with at least that number of citations each

WoS: SCIE / JCRQ2
Self-Citation Rate0%
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessHybrid
104articles/year
4.42% Gold OA•24.07% Original Research

Aims & Scope

Expert Review of Clinical Immunology (ISSN 1744-666X) provides expert analysis and commentary regarding the performance of new therapeutic and diagnostic modalities in clinical immunology. Members of the International Editorial Advisory Panel of Expert Review of Clinical Immunology are the forefront of their area of expertise. This panel works with our dedicated editorial team to identify the most important and topical review themes and the corresponding expert(s) most appropriate to provide commentary and analysis. All articles are subject to rigorous peer-review, and the finished reviews provide an essential contribution to decision-making in clinical immunology. Articles focus on the following key areas: • Therapeutic overviews of specific immunologic disorders highlighting optimal therapy and prospects for new medicines • Performance and benefits of newly approved therapeutic agents • New diagnostic approaches • Screening and patient stratification • Pharmacoeconomic studies • New therapeutic indications for existing therapies • Adverse effects, occurrence and reduction • Prospects for medicines in late-stage trials approaching regulatory approval • Novel treatment strategies • Epidemiological studies • Commentary and comparison of treatment guidelines Topics include infection and immunity, inflammation, host defense mechanisms, congenital and acquired immunodeficiencies, anaphylaxis and allergy, systemic immune diseases, organ-specific inflammatory diseases, transplantation immunology, endocrinology and diabetes, cancer immunology, neuroimmunology and hematological diseases.

Topics Covered (Recognized by AI)
Medicine93.2%Biology86.4%Immunology81.6%Internal medicine80.9%Genetics64%Pathology63.3%Disease47.9%Chemistry39%Biochemistry37.2%Immune system34.5%Antibody28.4%Intensive care medicine27.9%Surgery25.1%Psychology23.8%
Primary Research Areas

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI
JCRSCIE2026

IMMUNOLOGY

Q2
Rank75/183
IndexSCIE
JCISCIE2026

IMMUNOLOGY

Q3
Rank134/183
IndexSCIE

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year
2026Latest
IF4
Articles / Year81
Total Citations28
2025
IF3.7
Articles / Year109
Total Citations338
2024
IF3.9
Articles / Year108
Total Citations751
2023
IF4.4
Articles / Year149
Total Citations1,731
2022
IF5.124
Articles / Year129
Total Citations2,089

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #3,649Scopus Q2SCImago Profile
Scopus Coverage:2006-2026
Scopus Broad Areas:Immunology and MicrobiologyMedicine
Scopus Citation Rank (SJR)Q2
1.198

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q2
Citations / Doc (2 years)
4.07

Average citations received per document published in the 2-year window.

2-Year Citation Window
Estimated Publication Fee (APC)
$3,424 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations1,543
3-Year Documents367
Citable Documents327

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate47.9%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

ImmunologyQ2
Immunology and AllergyQ2
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: 0%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
3区 (Zone 3)Medicine
Minor Category (Specific Field):
3区IMMUNOLOGY
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
Not warned
2021
Not warned
2022
Not warned
2023
Not warned
2024
Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Expert Review of Clinical Immunology (acronym: erm, abbr: Expert Rev. Clin. Immunol, ISSN: 1744-666X) is a peer-reviewed international scholarly journal in the field of IMMUNOLOGY, published by Taylor and Francis Ltd. in United States since 2005. The periodical holds a Journal Impact Factor (JIF) of 4.00, ranking in quartile Q2 of Web of Science (SCIE), a Scopus SJR indicator of 1.198 (Q2), an H-index of 85.

The journal enforces rigorous peer evaluation with a publication frequency of Bimonthly, an annual output of approximately 104 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,424 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Open Access Model
Hybrid
Publisher
Taylor and Francis Ltd.
Publication Language
English
Frequency
Bimonthly
Founding Year
2005
Indexing & Databases
SCIEScopusPubMed
Editorial Address
EXPERT REVIEWS, UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, ENGLAND, N3 1QB

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: 1735926e-7f0f-43d6-a6d1-f0cf2ed96def
Database Updated: 2026-09-29